Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

Germany’s Merck KGaA sees emerging markets as bigger earnings driver than Europe

March 30, 2015
Life sciences
Germany’s Merck KGaA now considers the world’s emerging markets as a group, with China a major driver, to be a greater revenue-producer than Europe, unit CEO Bernd Reckmann said in an interview.
 
The head of the company’s life science and performance materials unit told China’s Global Times that even as the nation’s economy has become a more normal one, he sees the country providing continued double-digit growth for the company.
 
The emerging markets that include Latin America and all of Asia except Japan provided 38% of the company’s total revenue of $12.5 billion last year, while Europe provided 35%, the company said.
 
Reckmann said China’s slower rate of growth would be more than offset by its increasing healthcare needs and its efforts to encourage more innovation. Merck KGaA, he said, has added to its own investment and manufacturing plants in China, the latest a $104.6 million facility expected to be operational in 2017 to produce drugs on the country’s list of those considered essential.
 
E. Allan Gabor, president and CEO of Merck Serono China, told the Global Times he still considered China a good investment climate, particularly for companies eyeing long-term development.
 
By EJ Lane
 

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach